These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14586150)

  • 21. Ifosfamide.
    Zalupski M; Baker LH
    J Natl Cancer Inst; 1988 Jun; 80(8):556-66. PubMed ID: 3286879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ifosfamide in germ cell tumors.
    Einhorn LH
    Oncology; 2003; 65 Suppl 2():73-5. PubMed ID: 14586153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer.
    Malik IA; Mehboobali N; Iqbal MP
    Cancer Chemother Pharmacol; 1997; 39(6):561-5. PubMed ID: 9118472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    Mulder RL; Paulides M; Langer T; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2010 Feb; (2):CD006300. PubMed ID: 20166081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-agent ifosfamide in the treatment of anthracycline-refractory adult sarcomas.
    Lopez M; Carpano S; Amodio A; Gionfra T; Della Giulia M; Foggi P; Manfredi C; Del Monte G
    Clin Ter; 1998; 149(5):331-3. PubMed ID: 10052244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ifosfamide with regional hyperthermia in soft-tissue sarcomas.
    Schlemmer M; Wendtner CM; Issels RD
    Oncology; 2003; 65 Suppl 2():76-9. PubMed ID: 14586154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gynecologic Oncology Group studies with ifosfamide.
    Sutton GP; Blessing JA; Manetta A; Homesley H; McGuire W
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):31-4. PubMed ID: 1485172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
    Pratt CB
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):84-90. PubMed ID: 8677456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ifosfamide in the treatment of germ cell tumors.
    Nichols CR
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):65-73. PubMed ID: 8677452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence?
    Verweij J
    Ann Oncol; 1998 Aug; 9(8):807-9. PubMed ID: 9789601
    [No Abstract]   [Full Text] [Related]  

  • 33. Complete response to paclitaxel, ifosfamide, and cisplatin therapy in a case of ovarian ependymoma.
    Hino M; Kobayashi Y; Wada M; Hattori Y; Kurahasi T; Nakagawa H
    J Obstet Gynaecol Res; 2016 Nov; 42(11):1613-1617. PubMed ID: 27785897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Another example of the highly variable clinical course of recurrent/resistant/persistent ovarian cancer.
    Markman M
    Cancer Invest; 2006 Feb; 24(1):109. PubMed ID: 16467001
    [No Abstract]   [Full Text] [Related]  

  • 35. The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma.
    Erkisi M; Erkurt E; Ozbarlas S; Burgut R; Doran F; Seyrek E
    J Chemother; 1996 Jun; 8(3):224-8. PubMed ID: 8808721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of ifosfamide in the treatment of sarcomas.
    Dirix LY; Van Oosterom AT
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):39-45. PubMed ID: 2649984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study.
    Nardi M; De Marco S; Fabi A; Aloe A; Magnani E; Grandinetti P; Cognetti F
    Cancer Chemother Pharmacol; 2000; 45(6):513-5. PubMed ID: 10854141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ifosfamide in the treatment of breast cancer.
    Overmoyer BA
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):38-41. PubMed ID: 8677447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.